Company Update (NASDAQ:GILD): CORRECTED (OFFICIAL)-UPDATE 1-Aetna backs Gilead’s hepatitis C treatment, gets discount

[Reuters] – Aetna Inc, the third-largest U.S. health insurer, said it has negotiated a discount with Gilead Sciences Inc for its hepatitis C treatment and will offer it as the preferred choice to . . . → Read More: Company Update (NASDAQ:GILD): CORRECTED (OFFICIAL)-UPDATE 1-Aetna backs Gilead’s hepatitis C treatment, gets discount Similar Articles: Stock Update (NYSE:AET): CORRECTED (OFFICIAL)-UPDATE 1-Aetna backs Gilead’s hepatitis C treatment, gets discount Market Update: AbbVie Inc (NYSE:ABBV) – U.S. FDA approves AbbVie all-oral hepatitis C treatment Stock Update (NASDAQ:GILD): UK cost body backs pricey Gilead hepatitis pill for some patients